parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (2022 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 50	0.91
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 10404

DOCK10 in oligodendrocytes, braak+0.61 (p 0.084) → -0.20 (p 0.615)receipt 10411
DOCK10 in dopamine neurons, braak-0.16 (p 0.680) → +0.11 (p 0.785)receipt 10412

receipt 10412: DOCK10 in dopamine neurons, braak

power: full sample +0.04 (p 0.867, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.800, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.894, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.20, sign flips 4; without severely affected donors +0.04 (p 0.867, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DOCK10 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10411: DOCK10 in oligodendrocytes, braak

power: full sample +0.19 (p 0.460, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.579, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.39 (p 0.107, n 18). could be the mix.
skeptic: leave-one-out range +0.09 to +0.33, sign flips 0; without severely affected donors +0.19 (p 0.460, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DOCK10 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts